UA43385C2 - Спосіб лікування синдрому дефіциту уваги/гіперактивності - Google Patents

Спосіб лікування синдрому дефіциту уваги/гіперактивності

Info

Publication number
UA43385C2
UA43385C2 UA97073620A UA97073620A UA43385C2 UA 43385 C2 UA43385 C2 UA 43385C2 UA 97073620 A UA97073620 A UA 97073620A UA 97073620 A UA97073620 A UA 97073620A UA 43385 C2 UA43385 C2 UA 43385C2
Authority
UA
Ukraine
Prior art keywords
treatment
hyperactivity syndrome
attention deficiency
deficiency
attention
Prior art date
Application number
UA97073620A
Other languages
English (en)
Inventor
Джон Х. ХІЛАЙГЕНСТЕЙН
Гарі Д. ТОЛЛЕФСОН
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA43385(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA43385C2 publication Critical patent/UA43385C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Томоксетин, інгібітор зворотного захоплення норепінефріну, застосовують для лікування синдрому дефіциту уваги/гіперативності.
UA97073620A 1995-01-11 1996-04-01 Спосіб лікування синдрому дефіциту уваги/гіперактивності UA43385C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder
PCT/US1996/000091 WO1996021430A1 (en) 1995-01-11 1996-01-04 Treatment of attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
UA43385C2 true UA43385C2 (uk) 2001-12-17

Family

ID=23463572

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97073620A UA43385C2 (uk) 1995-01-11 1996-04-01 Спосіб лікування синдрому дефіциту уваги/гіперактивності

Country Status (28)

Country Link
US (1) US5658590A (uk)
EP (1) EP0721777B1 (uk)
JP (2) JPH10512262A (uk)
KR (1) KR19980701276A (uk)
CN (2) CN1168095A (uk)
AT (1) ATE222757T1 (uk)
AU (1) AU688665B2 (uk)
BR (1) BR9606903A (uk)
CA (1) CA2209735C (uk)
CZ (1) CZ292226B6 (uk)
DE (2) DE69623141T2 (uk)
DK (1) DK0721777T3 (uk)
ES (1) ES2181845T3 (uk)
FI (1) FI119354B (uk)
FR (1) FR10C0041I2 (uk)
HU (1) HU227306B1 (uk)
LU (1) LU91238I2 (uk)
NL (1) NL300180I2 (uk)
NO (2) NO317027B1 (uk)
NZ (1) NZ301500A (uk)
PL (1) PL187573B1 (uk)
PT (1) PT721777E (uk)
RO (1) RO118374B1 (uk)
RU (1) RU2163802C2 (uk)
SI (1) SI0721777T1 (uk)
TR (1) TR199700627T1 (uk)
UA (1) UA43385C2 (uk)
WO (1) WO1996021430A1 (uk)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
DK1616572T3 (da) * 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
DZ3282A1 (fr) * 2000-03-07 2001-09-13 Lilly Co Eli Traitement du psoriasis
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
CA2467802A1 (en) * 2001-12-11 2003-06-19 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
WO2005020975A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
BRPI0511529A (pt) * 2004-05-27 2008-01-02 Warner Lambert Co combinação terapêutica para distúrbios de hiperatividade/déficit de atenção
WO2006004976A2 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of atomoxetine hydrochloride
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
CN1976894A (zh) * 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JP2008501721A (ja) * 2005-04-05 2008-01-24 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
RU2428226C1 (ru) * 2009-12-31 2011-09-10 Учреждение Российской академии медицинских наук Научный центр проблем здоровья семьи и репродукции человека Сибирского отделения РАМН Применение атомоксетина гидрохлорида, импульсного низкоинтенсивного электромагнитного поля и кислородного коктейля у детей с синдромом дефицита внимания с гиперактивностью
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN105705135A (zh) 2013-11-08 2016-06-22 伊莱利利公司 阿托莫西汀溶液
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
US5658590A (en) 1997-08-19
WO1996021430A1 (en) 1996-07-18
DE69623141D1 (de) 2002-10-02
NL300180I2 (nl) 2005-08-01
JP2005325139A (ja) 2005-11-24
CN1781480A (zh) 2006-06-07
RO118374B1 (ro) 2003-05-30
DE122005000011I1 (de) 2005-06-23
NO317027B1 (no) 2004-07-26
EP0721777A3 (en) 1997-03-05
TR199700627T1 (xx) 1998-01-21
DK0721777T3 (da) 2002-10-07
FI972922L (fi) 1997-07-09
CA2209735C (en) 2002-10-01
NO973170L (no) 1997-09-02
NO2005006I2 (no) 2006-06-19
BR9606903A (pt) 1997-10-21
CZ292226B6 (cs) 2003-08-13
NZ301500A (en) 2000-07-28
CN1168095A (zh) 1997-12-17
AU4693896A (en) 1996-07-31
AU688665B2 (en) 1998-03-12
DE122005000011I2 (de) 2006-02-09
MX9705117A (es) 1997-10-31
PL321273A1 (en) 1997-11-24
SI0721777T1 (en) 2003-02-28
JPH10512262A (ja) 1998-11-24
EP0721777B1 (en) 2002-08-28
PT721777E (pt) 2002-11-29
CA2209735A1 (en) 1996-07-18
ES2181845T3 (es) 2003-03-01
RU2163802C2 (ru) 2001-03-10
HUP9801283A3 (en) 1999-09-28
PL187573B1 (pl) 2004-08-31
HUP9801283A2 (hu) 1999-06-28
FR10C0041I1 (uk) 2010-10-15
NL300180I1 (nl) 2005-05-02
LU91238I2 (fr) 2006-07-03
KR19980701276A (ko) 1998-05-15
EP0721777A2 (en) 1996-07-17
ATE222757T1 (de) 2002-09-15
FR10C0041I2 (uk) 2011-04-29
HU227306B1 (en) 2011-03-28
FI972922A0 (fi) 1997-07-09
DE69623141T2 (de) 2003-04-24
NO973170D0 (no) 1997-07-08
FI119354B (fi) 2008-10-31
CZ214597A3 (cs) 1998-01-14

Similar Documents

Publication Publication Date Title
NO973170D0 (no) Behandling av oppmerksomhets-svikt/hyperaktivitetsforstyrrelser
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
EA200000351A1 (ru) Лечение кондуктивных нарушений
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
DE69632630D1 (de) Enzym mit aminopeptidaseactivität
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
PT942751E (pt) Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores
NO950656L (no) Fremgangsmåte for å behandle oljeholdig formasjon
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
MY136367A (en) Treatment of cognitive failure
WO2001066101A3 (en) Treatment of psoriasis
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
ES2001836T3 (es) Metodo para tratar lentes de contacto.
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
PT1054671E (pt) Nova utilizacao da ropivacaina para o controlo da dor
AU2001282832A1 (en) New use of quetiapine
BR0112460A (pt) Método para tratamento de sépsis
NO20006314L (no) Prenyltransferase-inhibitorer
ES2107302T3 (es) Metodo para la depuracion destructiva de gas de cloruro de metilo.
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
DE69927985D1 (de) Verwendung von misoprostol oder/und misoprostol saüre zur herstellung eines arzneimittels zur behandlung weiblicher sexualer störung
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці